L
Luca Richeldi
Researcher at Catholic University of the Sacred Heart
Publications - 422
Citations - 36397
Luca Richeldi is an academic researcher from Catholic University of the Sacred Heart. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Nintedanib. The author has an hindex of 63, co-authored 376 publications receiving 27393 citations. Previous affiliations of Luca Richeldi include Boston University & University of Modena and Reggio Emilia.
Papers
More filters
Journal ArticleDOI
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management
Ganesh Raghu,Harold R. Collard,Jim J. Egan,Fernando J. Martinez,Juergen Behr,Kevin K. Brown,Thomas V. Colby,Jean-François Cordier,Kevin R. Flaherty,Joseph A. Lasky,David A. Lynch,Jay H. Ryu,Jeffrey J. Swigris,Athol U. Wells,Julio Ancochea,Demosthenes Bouros,Carlos Roberto Ribeiro de Carvalho,Ulrich Costabel,Masahito Ebina,David M. Hansell,Takeshi Johkoh,Dong Soon Kim,Talmadge E. King,Yasuhiro Kondoh,Jeffrey L. Myers,Nestor L. Müller,Andrew G. Nicholson,Luca Richeldi,Moisés Selman,Rosalind F. Dudden,Barbara S. Griss,Shandra Protzko,Holger J. Schünemann +32 more
TL;DR: This document represents the current state of knowledge regarding idiopathic pulmonary fibrosis, and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course.
Journal ArticleDOI
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
Luca Richeldi,Roland M. du Bois,Ganesh Raghu,Arata Azuma,Kevin K. Brown,Ulrich Costabel,Vincent Cottin,Kevin R. Flaherty,David M. Hansell,Yoshikazu Inoue,Dong Soon Kim,Martin Kolb,Andrew G. Nicholson,Paul W. Noble,Moisés Selman,Hiroyuki Taniguchi,Michèle Brun,Florence Le Maulf,Mannaig Girard,Susanne Stowasser,Rozsa Schlenker-Herceg,Bernd Disse,Harold R. Collard +22 more
TL;DR: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintinganib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.
Journal ArticleDOI
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
William D. Travis,Ulrich Costabel,David M Hansell,Talmadge E. King,David A. Lynch,Andrew G. Nicholson,Christopher J. Ryerson,Jay H. Ryu,Moisés Selman,Athol U. Wells,Jurgen Behr,Demosthenes Bouros,Kevin K. Brown,Thomas V. Colby,Harold R. Collard,Carlos Robalo Cordeiro,Vincent Cottin,Bruno Crestani,Marjolein Drent,Rosalind F. Dudden,Jim Egan,Kevin R. Flaherty,Cory M. Hogaboam,Yoshikazu Inoue,Takeshi Johkoh,Dong Soon Kim,M Kitaichi,James E. Loyd,Fernando J. Martinez,Jeffrey L. Myers,Shandra Protzko,Ganesh Raghu,Luca Richeldi,Nicola Sverzellati,Jeffrey J. Swigris,Dominique Valeyre +35 more
TL;DR: This update is a supplement to the previous 2002 IIP classification document and outlines advances in the past decade and potential areas for future investigation.
Journal ArticleDOI
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu,Martine Remy-Jardin,Jeffrey L. Myers,Luca Richeldi,Christopher J. Ryerson,David J. Lederer,Juergen Behr,Vincent Cottin,Sonye K. Danoff,Ferran Morell,Kevin R. Flaherty,Athol U. Wells,Fernando J. Martinez,Arata Azuma,Thomas Bice,Demosthenes Bouros,Kevin K. Brown,Harold R. Collard,Abhijit Duggal,Liam Galvin,Yoshikazu Inoue,R. Gisli Jenkins,Takeshi Johkoh,Ella A. Kazerooni,Masanori Kitaichi,Shandra L Knight,George Mansour,Andrew G. Nicholson,Sudhakar Pipavath,Ivette Buendía-Roldán,Moisés Selman,William D. Travis,Simon L.F. Walsh,Kevin C. Wilson +33 more
TL;DR: The guideline panel provided recommendations related to the diagnosis of IPF, including a conditional recommendation for multidisciplinary discussion and a strong recommendation against measurement of serum biomarkers for the sole purpose of distinguishing IPF from other ILDs.
Journal ArticleDOI
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline
Ganesh Raghu,Bram Rochwerg,Yuan Zhang,Carlos A. Cuello Garcia,Arata Azuma,Juergen Behr,Jan Brozek,Harold R. Collard,William Cunningham,Sakae Homma,Takeshi Johkoh,Fernando J. Martinez,Jeffrey L. Myers,Shandra Protzko,Luca Richeldi,David Rind,Moisés Selman,Arthur C. Theodore,Athol U. Wells,Henk C. Hoogsteden,Holger J. Schünemann +20 more
TL;DR: In this article, the authors updated the American Thoracic Society/European Respiratory Society/Japanese Rensenshine Society/Latin American thoracic Association guideline on idiopathic pulmonary fibrosis treatment using systematic reviews and meta-analyses.